Kamil R Kranc

9PUBLICATIONS
88CO-AUTHORS
Haematological tumoursMolecular targetsMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 12, 2026
RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.

|Aug 26, 2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.

Vilma Dembitz, Hannah Lawson, Richard Burt

|Apr 18, 2024
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.

Hannah Lawson, James P Holt-Martyn, Vilma Dembitz

|Apr 14, 2023
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.

Keith Woodley, Laura S Dillingh, George Giotopoulos

|Aug 09, 2022
MYC sensitises cells to apoptosis by driving energetic demand.

Joy Edwards-Hicks, Huizhong Su, Maurizio Mangolini

|Jul 14, 2018
Ca2+tapulting HSCs into action.

Amelie V Guitart, Andrew J Finch, Kamil R Kranc

Pageof 2

Frequent Collaborators

4 joint publications

Andrew J Finch

3 joint publications

Vilma Dembitz

3 joint publications

Jozef Durko

3 joint publications

Christopher Mapperley